Anti-SARS-CoV-2 IgY (Stanford University)

N/A

Report date: 2025/12/15 20:00:38

Base Information

Drug NameAnti-SARS-CoV-2 IgY (Stanford University)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesStanford University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDx&Vx Co LtdStanford University
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A